CTI Life Sciences raises $134 mln in first close of Fund II, boosts staff
Canadian venture capital firm CTI Life Sciences has secured $134 million in the initial close of its second partnership, CTI II, earmarked for investments in biotherapeutics and other life sciences companies. The result puts CTI II within reach of the $150 million target set for the fund, which is expected to wrap up by mid-2015, said Ken Pastor, co-founder and general partner of the Montréal-based firm.
15 January 2015•3 mins read
